EUVIMEDEUVIMED entdecken
Crossref

Anti‐factor Xa and activated partial thromboplastin time strategies for unfractionated heparin dosing after HeartMate 3 left ventricular assist device implantation

Iris Feng, Paul A Kurlansky, Tanner R Powley, Melissa A Hynds, Christine G Yang, Andrew Eisenberger, Jonathan M Hastie, Lauren D Sutherland, Melana Yuzefpolskaya, Paolo C Colombo, Gabriel T Sayer, Nir Y Uriel und 2 weitere

Artificial Organs · 2025

DOI: 10.1111/aor.14885 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Artificial Organs, 2025. Verfasst von Iris Feng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiothoracic and Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, New York, USA. Hauptthemen laut MEDLINE: Heart-Assist Devices, Heparin, Anticoagulants, Factor Xa Inhibitors. Die Arbeit nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

No clear guidelines exist for perioperative anticoagulation management after durable left ventricular assist device insertion. In this study, we sought to compare outcomes between anti‐factor Xa (FXa) and activated partial thromboplastin time (aPTT) in monitoring unfractionated heparin (UFH) dosing after HeartMate 3 (HM3) insertion.

Methods

This is a single‐center retrospective review of patients who received UFH after HM3 insertion between 01/2020–12/2022. Post‐operative UFH dose was titrated by aPTT goal 45–60 sec ( n = 53) or FXa goal 0.1–0.2 U/mL ( n = 59). Baseline differences between cohorts were balanced by inverse probability treatment weighting.

Results

At baseline, unadjusted FXa patients were more likely to be white (47.5% vs. 35.8%, p < 0.001), INTERMACS 1–2 (69.5% vs. 47.2%, p = 0.013), have history of coronary artery disease (66.1% vs. 43.4%, p = 0.026), and lower eGFR (54.1 vs. 63.7 mL/min/1.73 m 2 , p = 0.029) compared to the aPTT group. After adjusting for several bleeding/thrombosis risk factors, 97.5% of FXa and 91.0% of aPTT patients reached therapeutic levels with comparable UFH duration and maximum dose. Moreover, in‐hospital mortality (2.5% vs. 3.1%, p = 0.842), major bleeding events (4.2% vs. 9.2%, p = 0.360), and thromboembolic events (21.8% vs. 10.1%, p = 0.151) remained without significant differences between FXa and aPTT cohorts. There was a high degree of variability in FXa ( r 2 = 0.20) and aPTT ( r 2 = 0.22) values for any given UFH dose.

Conclusions

No differences in frequency of bleeding or thromboembolic events were observed in this study between FXa versus aPTT cohorts after HM3 implantation. More longitudinal studies are warranted to determine whether or not one assay is superior to the other.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart-Assist DevicesHeparinAnticoagulantsFactor Xa InhibitorsHumansPartial Thromboplastin TimeMaleRetrospective StudiesFemaleMiddle AgedAgedAdultFactor Xa

Stichwörter der Autor:innen

HeartMate 3anticoagulationanti‐factor Xaheart failureleft ventricular assist devicemechanical circulatory support

Substanzen

HeparinAnticoagulantsFactor Xa InhibitorsFactor Xa

Autor:innen und Institutionen

  • Division of Cardiothoracic and Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, New York, USA.
  • Center of Innovation and Outcomes Research, Department of Surgery, Columbia University, New York, New York, USA.
  • Division of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
  • Department of Anesthesiology, Columbia University Irving Medical Center, New York, New York, USA.
  • Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.

ORCID-Profile: Koji Takeda

Zitieren

APA

Feng, I., Kurlansky, P. A., Powley, T. R., Hynds, M. A., Yang, C. G., Eisenberger, A., Hastie, J. M., Sutherland, L. D., Yuzefpolskaya, M., Colombo, P. C., Sayer, G. T., Uriel, N. Y., Naka, Y., & Takeda, K. (2025). Anti‐factor Xa and activated partial thromboplastin time strategies for unfractionated heparin dosing after HeartMate 3 left ventricular assist device implantation. Artificial Organs. https://doi.org/10.1111/aor.14885

Vancouver

Feng I, Kurlansky PA, Powley TR, Hynds MA, Yang CG, Eisenberger A, et al. Anti‐factor Xa and activated partial thromboplastin time strategies for unfractionated heparin dosing after HeartMate 3 left ventricular assist device implantation. Artificial Organs. 2025. doi:10.1111/aor.14885

BibTeX
@article{Feng2025,
  author = {Feng, Iris and Kurlansky, Paul A and Powley, Tanner R and Hynds, Melissa A and Yang, Christine G and Eisenberger, Andrew and Hastie, Jonathan M and Sutherland, Lauren D and Yuzefpolskaya, Melana and Colombo, Paolo C and Sayer, Gabriel T and Uriel, Nir Y and Naka, Yoshifumi and Takeda, Koji},
  title = {Anti‐factor Xa and activated partial thromboplastin time strategies for unfractionated heparin dosing after HeartMate 3 left ventricular assist device implantation},
  journal = {Artificial Organs},
  year = {2025},
  doi = {10.1111/aor.14885}
}
Kostenlos starten →